SELANK · DECODED
Selank
Decoded · Russian Prescription Drug · Anxiolytic
BY THE NUMBERS
HOW IT WORKS
A synthetic hexapeptide analog of tuftsin, an endogenous immunomodulatory tetrapeptide. Proposed to modulate GABAergic and serotonergic activity, producing anxiolytic effects, with BDNF upregulation also proposed. The precise receptor target in humans is not established; mechanism is inferred from behavioral animal models and limited Russian clinical work that does not meet GCP standard.
WHERE IT CAME FROM
Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics in Moscow, the same institution responsible for Semax. It is based on tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) produced by the spleen that has both immune-modulating and behavioral effects, to which the same Pro-Gly-Pro stabilization sequence used in Semax was appended. Tuftsin itself has been studied since the 1970s for its role in activating macrophages and natural killer cells in immune defense, and for its central nervous system effects including anxiolytic (anti-anxiety) properties.
Selank received Russian regulatory approval for the treatment of generalized anxiety disorder (GAD) and is used clinically in Russia through intranasal administration. The proposed mechanism involves modulation of GABAergic signaling and enkephalin metabolism (enkephalins are endogenous opioid peptides involved in pain and stress modulation). Russian clinical data suggests anxiolytic effects comparable to some benzodiazepine class drugs, but with a different side effect profile and without the dependency risk associated with benzodiazepines. None of this has been tested in controlled Western trials.
THE STUDIES
WHAT THE STUDIES SHOW
RUSSIAN DATA
- ▸Anxiolytic effect in GAD patients (Russian prescription approval basis)
- ▸No dependency or withdrawal noted in Russian trials
- ▸GABA and enkephalin modulation proposed mechanism
- ▸Intranasal administration effective per Russian studies
PRECLINICAL
- ▸Tuftsin-mediated immune activation (macrophages, NK cells)
- ▸Anti-anxiety behavior in animal models
- ▸Enkephalin metabolism modulation
- ▸BDNF-adjacent effects in some preclinical models
NOT ESTABLISHED (WESTERN)
- ▸Efficacy for anxiety in Western population (no controlled trial data)
- ▸Safety compared to approved anxiolytics
- ▸Effective dose range outside Russian clinical context
- ▸Long-term cognitive and behavioral effects
SIDE EFFECTS
REPORTED (RUSSIAN CLINICAL + ANECDOTAL)
- ▸Nasal irritation (intranasal route)
- ▸Mild fatigue or drowsiness in some users
- ▸Occasional mild headache
- ▸Russian data notes favorable tolerability vs. benzodiazepines
NOTABLE / MONITOR FOR
- ▸No Western safety data from controlled trials
- ▸GABAergic modulation: potential interaction with other anxiolytics, alcohol, or CNS depressants
- ▸Grey market supply: purity and concentration unverified
- ▸Self-treating anxiety without physician involvement carries risk, regardless of compound
REGULATORY STATUS
Selank is a registered prescription drug in Russia for generalized anxiety disorder. It is not approved by the FDA, EMA, or any Western regulatory authority. Unlike some of the Category 2 compounds removed on April 15, 2026, Selank's US regulatory status is less clearly defined. It was not among the 12 compounds explicitly removed from the Category 2 list that date. It is not on any FDA-approved 503A bulk substances list. Obtainable in the US only through grey market or international channels.
PROS & CONS
PROS
- +Russian prescription approval for GAD: reviewed by a national regulator with documented clinical prescribing history for a specific indication
- +Russian data suggests anxiolytic potency without benzodiazepine-class side effects
- +Tuftsin-based mechanism has biological grounding in endogenous immune function
- +Intranasal route avoids injection
- +Decades of Russian clinical use provides some real-world safety feedback
CONS
- −No Western Phase 2 or Phase 3 data for any indication
- −Other anxiolytics with Phase 3 evidence in Western trials exist; their evidence profiles and regulatory status differ from Selank's
- −Not on Category 2 removal list. Regulatory status is less clear than Semax.
- −Grey market supply with no Western quality control
- −Self-treating anxiety with an unapproved compound is a significant clinical risk
- −Russian trial methodology does not meet Western GCP standards
DAILY PEPTIDE VERDICT
RANKING
Selank occupies an unusual position: it has a legitimate Russian prescription for a specific condition (generalized anxiety disorder), which is more clinical specificity than most grey market compounds can claim. The anxiolytic mechanism is grounded in real pharmacology: tuftsin, GABAergic signaling, enkephalin metabolism. The relevant context is that GAD has multiple FDA-approved treatments, from SSRIs to SNRIs to buspirone to benzodiazepines, all with Western Phase 3 data. Using Selank for anxiety means using a Russian-approved compound where no Western Phase 3 data exists. The Western evidence standard for this indication has not been met. For healthy adult cognitive optimization, the primary grey market use, the evidence base is thinner still.
DISCLAIMER · EDUCATIONAL USE ONLY
This document is for educational and informational purposes only. Selank does not hold general FDA approval for human use. Information here synthesizes publicly available research data and does not constitute medical advice.